Meticulous Research®—a leading global market research company, published a research report titled, ‘Europe Cancer Diagnostic Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)–Global Forecast to 2031.’
According to this latest publication from Meticulous Research®, cancer is still one of the toughest health issues in Europe, and diagnostics are right at the center of the fight. The Europe Cancer Diagnostics Market could be worth about $12.21 billion by 2031, growing at roughly 5.6% CAGR. That number does not just come from the rise in cancer cases it also reflects stronger government support for early cancer diagnosis and a shift toward better tools for oncology testing. Hospitals and labs are investing more in cancer imaging and molecular approaches. Some of the fastest growth is in leukemia diagnostics, where precision testing is becoming a bigger part of treatment decisions. At the same time, awareness programs have pushed more people to get cancer testing earlier, which naturally feeds into demand. But the market picture is not all smooth. Imaging systems cost a fortune, and not every clinic can afford them. There is also a shortage of trained professionals, and screening programs are not consistent across all countries. In some places, access is far better than in others. Even with those issues, the overall trend points forward new technology, better funding, and the push for personalized medicine are likely to keep this market moving up.
Key Players:
The key players operating in Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).
Europe Cancer Diagnostics Market: Future Outlook
The Europe cancer diagnostics market is segmented by product (In vitro diagnostics [instruments {polymerase chain reaction (PCR), microarray, immunoassay, sequencers, and other instruments}, consumables {kits & assays and reagents}, software & services], diagnostic imaging [instruments {computed tomography (CT), magnetic resonance imaging (MRI), mammography, ultrasound, and other instruments}, consumables {syringes and injectors, contrast delivery systems, phantoms, skin markers, contrast agents, and other consumables}, software & services]), cancer type (breast cancer, lung cancer, colorectal cancer, prostate cancer, other cancer types), end user (hospitals & diagnostic laboratories, diagnostic imaging centers, pharmaceutical & biotechnology companies, academic & research institutes) and geography. The study also evaluates industry competitors and analyzes the market at country levels.
In Vitro Diagnostics Outpaces Imaging in Europe’s Cancer Diagnostics Market
When you break the Europe Cancer Diagnostics Market down by product, two main categories stand out: in vitro diagnostics (IVD) and diagnostic imaging. Of these, IVD is set to grow the fastest between 2024 and 2031. The reasons are not hard to see. Sequencing costs have dropped sharply, precision oncology testing is gaining traction,